|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.800 USD | 0.00% |
|
+0.56% | -80.07% |
| 07-16 | EnGene Therapeutics Initiates Planned BLA Submission For Detalimogene Voraplasmid And Provides Updates On LEGEND Phase 2 Trial | CI |
| 07-16 | Engene Therapeutics Inc. Announces Board Changes | CI |
Company Valuation: enGene Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: October | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | 451.1 | 369.1 | 120.6 | - | - |
| Change | - | - | -18.18% | -67.33% | - | - |
| Enterprise Value (EV) 1 | - | 236 | 190.7 | -80.66 | -6.9 | -1.807 |
| Change | - | - | -19.19% | -142.3% | 91.45% | 73.81% |
| P/E | -0.14x | -6.06x | -3.15x | -1.03x | -1.18x | -1.8x |
| PBR | - | 1.65x | 2.2x | 0.64x | 1.23x | 1.55x |
| PEG | - | 0.1x | -0.1x | 0x | 0.1x | 0.1x |
| Capitalization / Revenue | - | - | - | - | 19.5x | 3.34x |
| EV / Revenue | - | - | - | - | -1.12x | -0.05x |
| EV / EBITDA | - | -3.81x | -1.55x | 0.7x | 0.07x | 0.02x |
| EV / EBIT | - | -3.79x | -1.55x | 0.68x | 0.06x | 0.02x |
| EV / FCF | - | - | -1.89x | 0.57x | 0.05x | 0.01x |
| FCF Yield | - | - | -52.8% | 175% | 2,198% | 8,081% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -151.2 | -1.46 | -2.29 | -1.745 | -1.527 | -0.998 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 6.17 | 36.1 |
| EBITDA 1 | - | -61.97 | -122.7 | -114.8 | -101.4 | -113.3 |
| EBIT 1 | - | -62.3 | -123.2 | -119.4 | -118.5 | -105 |
| Net income 1 | -99.92 | -55.14 | -117.3 | -118.7 | -118.9 | -104.4 |
| Net Debt 1 | - | -215.2 | -178.4 | -201.2 | -127.5 | -122.4 |
| Reference price 2 | 21.695 | 8.850 | 7.210 | 1.800 | 1.800 | 1.800 |
| Nbr of stocks (in thousands) | - | 50,974 | 51,192 | 66,989 | - | - |
| Announcement Date | 1/29/24 | 12/19/24 | 12/22/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.03x | - | 0.7x | -.--% | 121M | |
| 20.56x | 7.11x | 14.62x | 1.42% | 68.12B | |
| 31.44x | 8.03x | 24.45x | 0.05% | 55.18B | |
| -82.67x | 15.62x | -80.83x | -.--% | 28.63B | |
| -14.87x | 5.23x | -6.82x | -.--% | 23.53B | |
| 30.46x | 5.97x | 15.8x | -.--% | 23.99B | |
| 25.58x | 4.78x | 15.97x | -.--% | 18.45B | |
| 47.61x | 19.33x | 49.78x | 0.08% | 15.83B | |
| -1250.29x | 38.99x | -15519.34x | -.--% | 16.44B | |
| 17.06x | 4.95x | 11.57x | -.--% | 13.4B | |
| Average | -117.62x | 12.22x | -1,547.41x | 0.15% | 26.37B | |
| Weighted average by Cap. | -68.07x | 10.40x | -961.78x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ENGN Stock
- Valuation enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
